Related Experiment Video
Updated: Jul 8, 2026
09:48
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
[Interactions between obstructive sleep apnea syndrome and insulin resistance]
Gláucia Carneiro1, Fernando Flexa Ribeiro Filho, Sônia Maria Togeiro
1Departamento de Clínica Médica, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo.
Arquivos Brasileiros De Endocrinologia E Metabologia
|December 25, 2007
Summary
Obstructive Sleep Apnea (OSA) is linked to cardiovascular issues. This review explores if OSA directly causes metabolic changes or if obesity is the main driver of these vascular risks.
Area of Science:
- Endocrinology
- Cardiology
- Sleep Medicine
Context:
- Obstructive Sleep Apnea (OSA) is increasingly recognized as a significant risk factor for cardiovascular and cerebrovascular diseases.
- The precise etiological link between OSA and vascular disease, whether direct or mediated by obesity, remains a subject of ongoing research and debate.
Purpose:
- To review existing evidence and elucidate the potential mechanisms by which Obstructive Sleep Apnea may contribute to vascular morbidity.
- To discuss the pathophysiology linking OSA to endocrine and metabolic alterations that predispose individuals to cardiovascular complications.
Summary:
- OSA is associated with numerous cardiovascular risk factors, including hypertension, obesity, insulin resistance, and type 2 diabetes.
- Potential mechanisms include OSA-induced endocrine and metabolic changes such as impaired insulin sensitivity, altered growth hormone secretion, inflammation, sympathetic nervous system activation, and hypothalamic-pituitary-adrenal (HPA) axis dysregulation.
- These OSA-related pathophysiological changes may independently predispose individuals to vascular disease.
Impact:
- Clarifies the complex relationship between Obstructive Sleep Apnea and cardiovascular health.
- Provides insights into the pathophysiological pathways underlying OSA comorbidities.
- Highlights the need for further research into the direct effects of OSA on metabolic and vascular systems.
Related Concept Videos
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...